NCT01923727View on ClinicalTrials.gov

Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

May 31, 2016

Study Completion Date

June 30, 2016

Conditions
Metastatic Prostate Cancer
Interventions
BIOLOGICAL

[89Zr]Df-IAB2M

A single intravenous infusion of 5 mCi of \[89Zr\]Df-IAB2M in a mass dose of 10 mg, 20mg or 50mg.

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors

Lead Sponsor

ImaginAb, Inc.
All Listed Sponsors
lead

ImaginAb, Inc.

INDUSTRY